{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:50:09Z","timestamp":1793047809913,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007414","name":"Qassim University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["RGPIN-2020-05982"],"award-info":[{"award-number":["RGPIN-2020-05982"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.biopha.2022.113777","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T14:33:09Z","timestamp":1665066789000},"page":"113777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Critical assessment of the revised guidelines for vancomycin therapeutic drug monitoring"],"prefix":"10.1016","volume":"155","author":[{"given":"Abdullah","family":"Aljutayli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.G.","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahima","family":"Nekka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib2","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2022.113777_bib3","first-page":"3","article-title":"A Canadian perspective on the revised 2020 ASHP\u2013IDSA\u2013PIDS\u2013SIDP guidelines for vancomycin AUC-based therapeutic drug monitoring for serious MRSA infections","volume":"6","author":"Stewart","year":"2021","journal-title":"Off. J. Assoc. Med. Microbiol. Infect. Dis. Can."},{"key":"10.1016\/j.biopha.2022.113777_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2022.113777_bib5","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/jcph.1254","article-title":"Evaluation of the effectiveness of dose individualization to achieve therapeutic vancomycin concentrations","volume":"58","author":"Abulfathi","year":"2018","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113777_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02535-16","article-title":"Hal, Establishment of an AUC0\u201324 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0000000000000622","article-title":"Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections","volume":"41","author":"Clark","year":"2019","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.diagmicrobio.2018.06.022","article-title":"Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population","volume":"92","author":"Turner","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"12","key":"10.1016\/j.biopha.2022.113777_bib9","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jcph.1498","article-title":"Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients","volume":"59","author":"Suchartlikitwong","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2022.113777_bib10","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/jac\/dkx093","article-title":"Paepe, Dose optimization of piperacillin\/tazobactam in critically ill children","volume":"72","author":"De Cock","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.biopha.2022.113777_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12098-019-03162-5","article-title":"AUC- vs. Trough-Guided Monitoring of Vancomycin in Infants","volume":"87","author":"Alsultan","year":"2020","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.biopha.2022.113777_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkab048","article-title":"AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics","author":"Jorgensen","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.biopha.2022.113777_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jpids\/piaa057","volume":"9","author":"Rybak","year":"2020","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"issue":"11","key":"10.1016\/j.biopha.2022.113777_bib14","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/jac\/dkaa320","article-title":"Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure","volume":"75","author":"Shingde","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2022.113777_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.biopha.2022.113777_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Prog. Biomed."},{"issue":"1","key":"10.1016\/j.biopha.2022.113777_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.biopha.2022.113777_bib18","unstructured":"A. Rohatgi, WebPlotDigitizer, 2021. \u3008https:\/\/automeris.io\/WebPlotDigitizer\u3009. (Accessed August 2021 2021)."},{"key":"10.1016\/j.biopha.2022.113777_bib19","article-title":"Pharmacokinetic equations versus bayesian guided vancomycin monitoring: pharmacokinetic model and model-informed precision dosing trial simulations","author":"Aljutayli","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2022.113777_bib20","unstructured":"G. Drusano, P. Ambrose, S. Bhavnani, C. Rubino, A. Forrest, A. Louie, T. Lodise, K.J.M.I.D.S.A. Rodvold, Vancomycin dose recommendations for hospital-, ventilator-or health care-associated pneumonia and the attainment of vancomycin trough concentrations of 15\u201320 mg\/L: cognitive dissonance, 4 (2007)."},{"key":"10.1016\/j.biopha.2022.113777_bib21","doi-asserted-by":"crossref","unstructured":"N. Patel, M.P. Pai, K.A. Rodvold, B. Lomaestro, G.L. Drusano, T.P.J.Cid Lodise, Vancomycin: we Can. 't Get. there here, 52, 8, 2011, pp. 969\u2013974.","DOI":"10.1093\/cid\/cir078"},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1128\/AAC.32.6.848","article-title":"Vancomycin pharmacokinetics in patients with various degrees of renal function","volume":"32","author":"Rodvold","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.113777_bib23","unstructured":"D.Z. D\u2032Argenio, A. Schumitzky, X.J.B.S.R. Wang, Los Angeles, CA, ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software, (2009)."},{"key":"10.1016\/j.biopha.2022.113777_bib24","first-page":"1","article-title":"An update on population pharmacokinetic analyses of vancomycin, Part I: in adults","author":"Aljutayli","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40262-018-0727-5","article-title":"Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations","volume":"58","author":"Colin","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.113777_bib26","doi-asserted-by":"crossref","unstructured":"A. Aljutayli, D.J. Thirion, G. Bonnefois, F.J.C. Nekka, T. Science, Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model\u2010informed precision dosing trial simulations, (2022).","DOI":"10.1111\/cts.13210"},{"issue":"1","key":"10.1016\/j.biopha.2022.113777_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/FTD.0000000000000359","article-title":"Is trough concentration of vancomycin predictive of the area under the curve? A clinical study in elderly patients","volume":"39","author":"Bel Kamel","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2022.113777_bib28","doi-asserted-by":"crossref","unstructured":"S.J. Jin, J.H. Yoon, B.S. Ahn, J.A. Chung, Y.G. Song, Under Calc. Area Conc. -Time Curve Based Serum Creat. Vancomycin Dosing, ic, 46, 1, 2014, pp. 21\u201329.","DOI":"10.3947\/ic.2014.46.1.21"},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcp.14144","article-title":"Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals","volume":"86","author":"Smit","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113777_bib30","doi-asserted-by":"crossref","unstructured":"J.H.J.E.Jo.P.S. Proost, Combined proportional and additive residual error models in population pharmacokinetic modelling, 109 (2017) S78-S82.","DOI":"10.1016\/j.ejps.2017.05.021"},{"key":"10.1016\/j.biopha.2022.113777_bib31","doi-asserted-by":"crossref","unstructured":"P. Colucci, J. Grenier, C.S. Yue, J. Turgeon, M.P.J.Tdm Ducharme, Perform. Differ. Popul. Pharmacokinet. Algorithms, 33, 5, 2011, pp. 583\u2013591.","DOI":"10.1097\/FTD.0b013e318232bc61"},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib32","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1378\/chest.130.4.947","article-title":"Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices","volume":"130","author":"Jeffres","year":"2006","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.biopha.2022.113777_bib33","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1086\/518451","article-title":"Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus","volume":"44","author":"Mohr","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"12","key":"10.1016\/j.biopha.2022.113777_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01293-17","article-title":"To study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.biopha.2022.113777_bib36","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0000000000000190","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin resistant Staphylococcus aureus bacteremia","volume":"37","author":"Hahn","year":"2015","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jmii.2015.08.027","article-title":"Vancomycin dosing and target attainment in children","volume":"50","author":"Hwang","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"10","key":"10.1016\/j.biopha.2022.113777_bib38","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1097\/INF.0000000000000817","article-title":"Correlation of a vancomycin pharmacokinetic model and trough serum concentrations in pediatric patients","volume":"34","author":"Ploessl","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13318-019-00568-6","article-title":"Clinical pharmacokinetics of vancomycin in critically ill children","volume":"44","author":"Sridharan","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40121-015-0067-9","article-title":"Predictive performance of a vancomycin population pharmacokinetic model in neonates","volume":"4","author":"Stockmann","year":"2015","journal-title":"Infect. Dis. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib41","doi-asserted-by":"crossref","first-page":"e01647","DOI":"10.1128\/AAC.01647-17","article-title":"Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates","volume":"62","author":"Tseng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2022.113777_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bcpt.13303","article-title":"Desired vancomycin trough concentration to achieve an AUC0-24\/MIC \u2265400 in Chinese children with complicated infectious diseases","volume":"126","author":"Zhang","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113777_bib43","first-page":"41","article-title":"Vancomycin AUC\/MIC and corresponding troughs in a pediatric population","volume":"22","author":"Kishk","year":"2017","journal-title":"J. Pedia Pharm. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib44","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MPH.0000000000000470","article-title":"Vancomycin therapeutic targets and nephrotoxicity in critically ill children with cancer","volume":"38","author":"Seixas","year":"2016","journal-title":"J. Pediatr. Hematol. \/Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2022.113777_bib45","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1128\/AAC.03620-14","article-title":"Association between vancomycin trough concentration and area under the concentration-time curve in neonates","volume":"58","author":"Frymoyer","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib46","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40262-020-00866-2","article-title":"An update on population pharmacokinetic analyses of vancomycin, part I: in adults","volume":"59","author":"Aljutayli","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.biopha.2022.113777_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","article-title":"Vancomycin","volume":"51","author":"Marsot","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.biopha.2022.113777_bib48","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/jac\/dkab145","article-title":"Comment on: AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics","volume":"76","author":"Avedissian","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"646","key":"10.1016\/j.biopha.2022.113777_bib49","article-title":"Right dose, right now: development of autokinetics for real time model informed precision antibiotic dosing decision support at the bedside of critically ill patients","volume":"11","author":"Roggeveen","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113777_bib50","doi-asserted-by":"crossref","first-page":"e02543","DOI":"10.1128\/AAC.02543-18","article-title":"External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care unit patients","volume":"63","author":"Guo","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib51","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.01708-10","article-title":"Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens","volume":"55","author":"Roberts","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00134-006-0470-5","article-title":"Navarro, Pharmacokinetic\/pharmacodynamic analysis of vancomycin in ICU patients","volume":"33","author":"del Mar Fern\u00e1ndez de Gatta Garcia","year":"2007","journal-title":"Intensive Care Med."},{"issue":"5","key":"10.1016\/j.biopha.2022.113777_bib53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2710.2006.00762.x","article-title":"Population pharmacokinetic parameters of vancomycin in critically ill patients","volume":"31","author":"Llopis\u2010Salvia","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2022.113777_bib54","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-014-0164-z","article-title":"Vancomycin pharmacokinetic and pharmacodynamic models for critically ill patients with post-sternotomy mediastinitis","volume":"53","author":"Mangin","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.biopha.2022.113777_bib55","doi-asserted-by":"crossref","first-page":"e01249","DOI":"10.1128\/AAC.01249-17","article-title":"Influence of mechanical ventilation on the pharmacokinetics of vancomycin administered by continuous infusion in critically ill patients","volume":"61","author":"Medell\u00edn-Garibay","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2125.2010.03679.x","article-title":"Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic\/pharmacodynamic simulation","volume":"70","author":"Revilla","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib57","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijantimicag.2013.01.018","article-title":"Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?","volume":"41","author":"Udy","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib58","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1128\/AAC.34.6.1165","article-title":"Application of a Bayesian method to monitor and adjust vancomycin dosage regimens","volume":"34","author":"Hurst","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.113777_bib59","series-title":"R for data science","author":"Wickham","year":"2017"},{"issue":"12","key":"10.1016\/j.biopha.2022.113777_bib60","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1128\/AAC.49.12.4934-4941.2005","article-title":"Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies","volume":"49","author":"Buelga","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib61","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/FTD.0000000000000490","article-title":"Hospitalized patients with and without hemodialysis have markedly different vancomycin pharmacokinetics: a population pharmacokinetic model-based analysis","volume":"40","author":"Goti","year":"2018","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib62","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/AAC.44.2.278-282.2000","article-title":"A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population","volume":"44","author":"Lamarre","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.113777_bib63","series-title":"Open Forum Infectious Diseases","first-page":"S575","article-title":"1574. Predictive ability and bias of vancomycin population PK models in an obese adult population","author":"Sabourenkov","year":"2019"},{"key":"10.1016\/j.biopha.2022.113777_bib64","series-title":"SpringerLink (Service en ligne), Statistical Analysis of Microbiome Data with R, Springer Singapore: Imprint","author":"Xia","year":"2018"},{"issue":"3","key":"10.1016\/j.biopha.2022.113777_bib65","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/FTD.0b013e31806db3f5","article-title":"Renal drug clearance in preterm neonates: relation to prenatal growth","volume":"29","author":"Allegaert","year":"2007","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.biopha.2022.113777_bib66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2006.02725.x","article-title":"Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance","volume":"63","author":"Anderson","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib67","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/FTD.0000000000000216","article-title":"Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration \u2265400 target","volume":"37","author":"Bhongsatiern","year":"2015","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.biopha.2022.113777_bib68","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s11095-013-1197-y","article-title":"A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates","volume":"31","author":"De Cock","year":"2014","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.biopha.2022.113777_bib69","doi-asserted-by":"crossref","first-page":"F221","DOI":"10.1136\/fn.81.3.F221","article-title":"Pharmacokinetics and dose requirements of vancomycin in neonates","volume":"81","author":"Grimsley","year":"1999","journal-title":"Arch. Dis. Child. - Fetal Neonatal Ed."},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib70","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1128\/AAC.48.4.1159-1167.2004","article-title":"Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates","volume":"48","author":"Kimura","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib71","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.01370-09","article-title":"Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination","volume":"54","author":"Lo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.biopha.2022.113777_bib72","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2125.2010.03736.x","article-title":"Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline","volume":"70","author":"Marqu\u00e9s-Mi\u00f1ana","year":"2010","journal-title":"Br. J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2022.113777_bib73","doi-asserted-by":"crossref","first-page":"F365","DOI":"10.1136\/adc.2010.196402","article-title":"Vancomycin prescription in neonates and young infants: toward a simplified dosage","volume":"96","author":"Oudin","year":"2011","journal-title":"Arch. Dis. Child Fetal Neonatal Ed."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib74","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/clpt.1994.120","article-title":"Population pharmacokinetics of vancomycin in neonates","volume":"56","author":"Seay","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib75","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/archdischild-2012-302765","article-title":"Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring","volume":"98","author":"Zhao","year":"2013","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.biopha.2022.113777_bib76","series-title":"Data Visualization: A Practical Introduction","author":"Healy","year":"2018"},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/AAC.25.4.433","article-title":"Pharmacokinetics of vancomycin in patients with various degrees of renal function","volume":"25","author":"Matzke","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib78","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/phar.1531","article-title":"Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections","volume":"35","author":"Adane","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.biopha.2022.113777_bib79","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/009127000104100901","article-title":"The influences of renal function and maturation on vancomycin elimination in newborns and infants","volume":"41","author":"Capparelli","year":"2001","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113777_bib80","doi-asserted-by":"crossref","first-page":"e02478","DOI":"10.1128\/AAC.02478-16","article-title":"Pilot study of a bayesian approach to estimate vancomycin exposure in obese patients with limited pharmacokinetic sampling","volume":"61","author":"Carreno","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.biopha.2022.113777_bib81","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1093\/jac\/dky310","article-title":"Dosing vancomycin in the super obese: less is more","volume":"73","author":"Crass","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib82","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.burns.2009.08.010","article-title":"Vancomycin pharmacokinetics in patients with severe burn injuries","volume":"36","author":"Dolton","year":"2010","journal-title":"Burns"},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib83","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/jac\/dky525","article-title":"Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data","volume":"74","author":"Germovsek","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2022.113777_bib84","doi-asserted-by":"crossref","unstructured":"F. Kloprogge, L.F. Hill, J. Booth, N. Klein, A.D. Irwin, G. Dixon, J.F. Standing, Revising Pediatr. Vancomycin Dosing Account. Nephrotox. a Pharmacokinet. -Pharmacodyn. Model 63 5 2019 e00067 19.","DOI":"10.1128\/AAC.00067-19"},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib85","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/FTD.0000000000000039","article-title":"Vancomycin monitoring in children using bayesian estimation","volume":"36","author":"Le","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2022.113777_bib86","doi-asserted-by":"crossref","unstructured":"J. Le, J.S. Bradley, W. Murray, G.L. Romanowski, T.T. Tran, N. Nguyen, S. Cho, S. Natale, I. Bui, T.M. Tran, E.V. Capparelli, Improv. Vancomycin Dosing Child. Using Area Curve Expo., 32, 4, 2013, pp. e155\u2013e163.","DOI":"10.1097\/INF.0b013e318286378e"},{"issue":"5","key":"10.1016\/j.biopha.2022.113777_bib87","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/jac\/dkp085","article-title":"Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations","volume":"63","author":"Thomson","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib88","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11095-020-02820-0","article-title":"Development of vancomycin dose individualization strategy by bayesian prediction in patients receiving continuous renal replacement therapy","volume":"37","author":"Oda","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2022.113777_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104278","article-title":"Optimisation of vancomycin exposure in neonates based on the best level of evidence","volume":"154","author":"Dao","year":"2020","journal-title":"Pharm. Res"},{"issue":"6","key":"10.1016\/j.biopha.2022.113777_bib90","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/jphp.13071","article-title":"A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function","volume":"71","author":"Liu","year":"2019","journal-title":"J. Pharm. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib91","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2125.2005.02547.x","article-title":"Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery","volume":"61","author":"Staatz","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113777_bib92","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2710.2008.01016.x","article-title":"Population pharmacokinetic analysis of vancomycin in patients with gram\u2010positive infections and the influence of infectious disease type","volume":"34","author":"Yamamoto","year":"2009","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113777_bib93","series-title":"Basic Clinical Pharmacokinetics","author":"Winter","year":"2004"},{"key":"10.1016\/j.biopha.2022.113777_bib94","article-title":"Implementation of vancomycin therapeutic monitoring guidelines: focus on bayesian estimation tools in neonatal and pediatric patients","author":"Han","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2022.113777_bib95","first-page":"77","article-title":"Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine","volume":"14","author":"Kildoo","year":"1990","journal-title":"Dev. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2022.113777_bib96","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00134-006-0470-5","article-title":"Pharmacokinetic\/pharmacodynamic analysis of vancomycin in ICU patients","volume":"33","author":"del Mar Fern\u00e1ndez de Gatta Garcia","year":"2007","journal-title":"Intensive Care Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222011660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222011660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:27:30Z","timestamp":1781782050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222011660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":96,"alternative-id":["S0753332222011660"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113777","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical assessment of the revised guidelines for vancomycin therapeutic drug monitoring","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113777"}}